We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+21.78%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$18.7M
(+13%)
Cap. Flow
-$2.45M
Cap. Flow
% of AUM
-1.53%
Top 10 Holdings %
Top 10 Hldgs %
58.41%
Holding
38
New
11
Increased
7
Reduced
9
Closed
8
Top Buys
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$7.55M |
| 2 |
Nektar Therapeutics
NKTR
|
+$7.49M |
| 3 |
Brookdale Senior Living
BKD
|
+$7.1M |
| 4 |
HCA Healthcare
HCA
|
+$6.67M |
| 5 |
Boston Scientific
BSX
|
+$4.81M |
Top Sells
| 1 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$10.6M |
| 2 |
HOLX
Hologic
HOLX
|
+$9.23M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$8.93M |
| 4 |
NXTM
NxStage Medical Inc.
NXTM
|
+$7.12M |
| 5 |
Amgen
AMGN
|
+$5.13M |
Sector Composition
| 1 | Healthcare | 94.78% |
| 2 | Industrials | 4.15% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
STRM
26
DELISTED
Streamline Health Solutions
STRM
| $1.16M | 0.73% |
75,867
| – | – |
|
|
RCM
27
DELISTED
R1 RCM Inc. Common Stock
RCM
| $795K | 0.5% |
+257,400
| New | +$736K |
|
|
ENTL
28
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $633K | 0.4% |
+45,837
| New | +$736K |
|
|
QTNT
29
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $350K | 0.22% |
1,250
-1,250
| -50% | -$319K |
|
|
30
Amgen
AMGN
$198B
| $2K | ﹤0.01% |
130
-30,870
| -100% | -$5.13M |
|
|
31
Bio-Rad Laboratories Class A
BIO
$8.07B
| – | – |
-49,000
| Closed | -$8.93M |
|
|
HOLX
32
DELISTED
Hologic
HOLX
| – | – |
-230,000
| Closed | -$9.23M |
|
33
Henry Schein
HSIC
$9.98B
| – | – |
-918
| Closed | -$164K |
|
34
Service Corp International
SCI
$10.9B
| – | – |
-125,000
| Closed | -$3.55M |
|
35
Stryker
SYK
$123B
| – | – |
-250
| Closed | -$27K |
|
|
LMNX
36
DELISTED
Luminex Corp
LMNX
| – | – |
-135,000
| Closed | -$2.73M |
|
|
IPXL
37
DELISTED
Impax Laboratories, Inc.
IPXL
| – | – |
-257,500
| Closed | -$3.41M |
|
|
ARIA
38
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-850,000
| Closed | -$10.6M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, Tamarack Advisers held 38 positions worth $160M, up 13% from $141M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Tamarack Advisers's Q1 2017 filing shows 11 new, 7 increased, 9 reduced and 8 closed positions. Its largest new stake was Walgreens Boots Alliance: 90,000 shares worth $7.47M. The largest sale was Ariad Pharmaceuticals Inc, an estimated $10.6M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier, followed by Industrials and Consumer Discretionary.
- Tamarack Advisers's largest Q1 2017 buy was Walgreens Boots Alliance: 90,000 shares worth $7.47M.
- Tamarack Advisers added most to Boston Scientific in Q1 2017, an estimated $4.81M increase.
- Tamarack Advisers's biggest Q1 2017 reduction was NxStage Medical Inc., cutting an estimated $7.12M.
- Tamarack Advisers fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $10.6M.
- Tamarack Advisers's ten largest holdings make up 58% of its $160M portfolio in Q1 2017.
- Tamarack Advisers opened 11 new positions and closed 8 in Q1 2017.
- Tamarack Advisers's portfolio value rose 13% quarter-over-quarter to $160M.
Based on Tamarack Advisers's 13F filing for Q1 2017, filed 12 May 2017.